ADPT Stock Recent News

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks is only for the most risk-tolerant investors.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles with profitability. On the top line, the company's clonoSEQ test volume increased 57% year-over-year in Q1 2023 and has room for continued robust growth. With a to-date fruitless foray into drug discovery but relationships with ~175 biopharma concerns, this diagnostic concern merited further investigation.

Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.

Adaptive is awaiting an approval from the FDA on solid-tumor therapy afami-cel. The company uses a T-cell receptor platform to engineer cancer therapies.